- Home
- NEWP vs DSGN Comparison
NEWP vs DSGN Comparison
Compare NEWP & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEWP
- DSGN
- Stock Information
- Founded
- NEWP 1972
- DSGN 2017
- Country
- NEWP Canada
- DSGN United States
- Employees
- NEWP N/A
- DSGN N/A
- Industry
- NEWP
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- NEWP
- DSGN Health Care
- Exchange
- NEWP Nasdaq
- DSGN Nasdaq
- Market Cap
- NEWP 264.1M
- DSGN 264.4M
- IPO Year
- NEWP N/A
- DSGN 2021
- Fundamental
- Price
- NEWP $1.48
- DSGN $5.80
- Analyst Decision
- NEWP Strong Buy
- DSGN Hold
- Analyst Count
- NEWP 1
- DSGN 3
- Target Price
- NEWP $5.00
- DSGN $7.00
- AVG Volume (30 Days)
- NEWP 365.6K
- DSGN 140.3K
- Earning Date
- NEWP 11-26-2024
- DSGN 11-07-2024
- Dividend Yield
- NEWP N/A
- DSGN N/A
- EPS Growth
- NEWP N/A
- DSGN N/A
- EPS
- NEWP N/A
- DSGN N/A
- Revenue
- NEWP N/A
- DSGN N/A
- Revenue This Year
- NEWP N/A
- DSGN N/A
- Revenue Next Year
- NEWP N/A
- DSGN N/A
- P/E Ratio
- NEWP N/A
- DSGN N/A
- Revenue Growth
- NEWP N/A
- DSGN N/A
- 52 Week Low
- NEWP $0.87
- DSGN $2.13
- 52 Week High
- NEWP $2.53
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- NEWP 38.51
- DSGN 50.20
- Support Level
- NEWP $1.47
- DSGN $5.32
- Resistance Level
- NEWP $1.78
- DSGN $7.77
- Average True Range (ATR)
- NEWP 0.12
- DSGN 0.58
- MACD
- NEWP -0.04
- DSGN 0.05
- Stochastic Oscillator
- NEWP 4.17
- DSGN 27.57
About NEWP New Pacific Metals Corp.
New Pacific Metals Corp is a Canadian Mining Issuer, in the business of exploring and developing precious metal properties in Bolivia. The company's projects which are also its reportable segments include Silver Sand; Carangas and Silverstrike.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.